Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew James Martin

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Trials|June 5, 2020
Changes to aspects of ongoing randomised controlled trials with fixed designsXanthi Coskinas, John Simes, Manjula Schou, et al.
International Urogynecology Journal|December 25, 2015
What is normal bladder neck anatomy?Cristina Naranjo-Ortiz, Ka Lai Shek, Andrew James Martin, et al.
Journal of Contaminant Hydrology|May 31, 2015
Matrix diffusion and sorption of Cs+, Na+, I- and HTO in granodiorite: Laboratory-scale results and their extrapolation to the in situ conditionYukio Tachi, Takanori Ebina, Chizuko Takeda, et al.
Acta Neurochirurgica|June 23, 2016
'Noises in the head': a prospective study to characterize intracranial sounds after cranial surgeryVinothan Sivasubramaniam, Varinder Singh Alg, Joseph Frantzias, et al.
The Journal of Vascular Access|February 23, 2010
The role of a vascular access surgeon in ventriculo-venous shunts in difficult hydrocephalusMohammad Ayaz Hossain, Adam Enver Frampton, Melissa Choo, et al.
Eclinicalmedicine|December 14, 2023
SCORE: a randomised controlled trial evaluating shared care (general practitioner and oncologist) follow-up compared to usual oncologist follow-up for survivors of colorectal cancerMichael Jefford, Jon D Emery, Andrew James Martin, et al.
The Lancet. Oncology|August 2, 2025
Prognostic and predictive value of baseline PSMA-PET total tumour volume and SUVmean in metastatic castration-resistant prostate cancer in ENZA-p (ANZUP1901): a substudy from a multicentre, open-label, randomised, phase 2 trialLouise Emmett, Nathan Papa, Shalini Subramaniam, et al.
European Urology|April 9, 2026
Prognostic Value of Interim PSMA-PET Total Tumor Volume for Overall Survival Within ENZA-p, A Randomized Phase 2 Trial of Enzalutamide Versus Enzalutamide Plus [<sup>177</sup>Lu] Lu-PSMA-617 (ANZUP1901)Louise Emmett, Nathan Papa, Oliver Sartor, et al.
The Lancet. Oncology|April 15, 2024
[<sup>177</sup>Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trialLouise Emmett, Shalini Subramaniam, Megan Crumbaker, et al.
The Lancet. Oncology|February 16, 2025
Overall survival and quality of life with [<sup>177</sup>Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trialLouise Emmett, Shalini Subramaniam, Megan Crumbaker, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Trials|June 5, 2020
Changes to aspects of ongoing randomised controlled trials with fixed designsXanthi Coskinas, John Simes, Manjula Schou, et al.
International Urogynecology Journal|December 25, 2015
What is normal bladder neck anatomy?Cristina Naranjo-Ortiz, Ka Lai Shek, Andrew James Martin, et al.
Journal of Contaminant Hydrology|May 31, 2015
Matrix diffusion and sorption of Cs+, Na+, I- and HTO in granodiorite: Laboratory-scale results and their extrapolation to the in situ conditionYukio Tachi, Takanori Ebina, Chizuko Takeda, et al.
Acta Neurochirurgica|June 23, 2016
'Noises in the head': a prospective study to characterize intracranial sounds after cranial surgeryVinothan Sivasubramaniam, Varinder Singh Alg, Joseph Frantzias, et al.
The Journal of Vascular Access|February 23, 2010
The role of a vascular access surgeon in ventriculo-venous shunts in difficult hydrocephalusMohammad Ayaz Hossain, Adam Enver Frampton, Melissa Choo, et al.
Eclinicalmedicine|December 14, 2023
SCORE: a randomised controlled trial evaluating shared care (general practitioner and oncologist) follow-up compared to usual oncologist follow-up for survivors of colorectal cancerMichael Jefford, Jon D Emery, Andrew James Martin, et al.
The Lancet. Oncology|August 2, 2025
Prognostic and predictive value of baseline PSMA-PET total tumour volume and SUVmean in metastatic castration-resistant prostate cancer in ENZA-p (ANZUP1901): a substudy from a multicentre, open-label, randomised, phase 2 trialLouise Emmett, Nathan Papa, Shalini Subramaniam, et al.
European Urology|April 9, 2026
Prognostic Value of Interim PSMA-PET Total Tumor Volume for Overall Survival Within ENZA-p, A Randomized Phase 2 Trial of Enzalutamide Versus Enzalutamide Plus [<sup>177</sup>Lu] Lu-PSMA-617 (ANZUP1901)Louise Emmett, Nathan Papa, Oliver Sartor, et al.
The Lancet. Oncology|April 15, 2024
[<sup>177</sup>Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trialLouise Emmett, Shalini Subramaniam, Megan Crumbaker, et al.
The Lancet. Oncology|February 16, 2025
Overall survival and quality of life with [<sup>177</sup>Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trialLouise Emmett, Shalini Subramaniam, Megan Crumbaker, et al.
Pageof 1